Healthcare company AbbVie (NYSE:ABBV) said on Monday that it has filed applications with the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for RINVOQ for the treatment of adults in 15 mg and 30 mg, once daily and adolescents in 15 mg, once daily with moderate to severe atopic dermatitis supported by data from three pivotal Phase 3 studies.
In all three studies, RINVOQ (upadacitinib) demonstrated significant improvement in skin clearance and reduction in itch in adults and adolescents with moderate to severe atopic dermatitis compared to placebo. RINVOQ met the co-primary endpoints of 75% improvement in the Eczema Area Severity Index from baseline and a validated Investigator's Global Assessment for Atopic Dermatitis, said the company.
Atopic dermatitis is reportedly characterized by a cycle of itching and scratching that leads to cracked, scaly, oozing skin, which intensifies with worsening disease severity.
The company stated RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. RINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT